Highlights:
- Phase 3 trials of COVAXIN has started
- COVAXIN is India’s own Coronavirus vaccine
- Vice Chancellor of Aligarh Muslim University has registered himself amongst first volunteers
The third phase of the clinical trials for India’s own COVID-19 vaccine, COVAXIN, has begun and the Vice Chancellor of Aligarh Muslim University (AMU), Professor Tariq Mansoor, is amongst the first to register themselves as the volunteers for the trails.
Prof Mansoor tweeted, “Volunteered myself for Phase III trial of COVID19 vaccine “Covaxin”- a study led by AMU in collaboration with ICMR & Bharat Biotech aimed at evaluating the safety and efficacy of this vaccine.”
I fervently appeal to everyone to volunteer/register for this trial and participate in this ground breaking research for developing better cures and treatment options. (2/2)@ugc_india @EduMinOfIndia @DrRPNishank @SanjayDhotreMP @PMOIndia @kishanreddybjp @naqvimukhtar @misskaul
— Tariq Mansoor (@ProfTariqManso1) November 10, 2020
In another tweet he requested other to volunteer for the trails saying, “I fervently appeal to everyone to volunteer/register for this trial and participate in this ground breaking research for developing better cures and treatment options,”.
The volunteers who will undergo the Phase 3 trial for COVAXIN will be entitled to receive travel expenses and other benefits as per guidelines of Indian Council of Medical Research (ICMR), an AMU spokesman said.
COVAXIN has been developed by pharma firm Bharat Biotech in collaboration with the Indian Council of Medical Research and its phase 3 of clinical trials began as JN Medical College and Hospital (JNMCH) of the Aligarh Muslim University (AMU).
The phase 3 trial of COVAXIN aims at evaluating the safety and efficacy of this coronavirus vaccine study which is being led in collaboration with the Indian Council of Medical Research (ICMR) and Bharat Biotech.
